LPCN Projected Dividend Yield
Lipocine Inc (New) ( NASDAQ : LPCN )Lipocine is clinical-stage biopharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products focusing on neuroendocrine and metabolic disorders. Co. has a license agreement for the development and commercialization its product candidate, TLANDO®, an oral testosterone replacement therapy comprised of testosterone undecanoate. Co.'s additional pipeline candidates, LPCN 1148 comprising a prodrug of testosterone, testosterone laurate, for the management of decompensated cirrhosis. Co. is conducting a Phase 2 POC study in male cirrhotic subjects to evaluate the therapeutic potential of LPCN 1148 for the management of sarcopenia. 20 YEAR PERFORMANCE RESULTS |
LPCN Dividend History Detail LPCN Dividend News LPCN Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |